Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows: - sale of pharmaceutical products (89.4%); - sale of food products (6.8%); - other (3.8%). All sales are in China.

Employees

5,461

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
09/26/09	CN¥17.11	-0.52%	70,65,236
06/26/06	CN¥17.20	-0.69%	86,97,678
05/26/05	CN¥17.32	-0.35%	1,03,76,069
04/26/04	CN¥17.38	+0.64%	1,69,13,177
03/26/03	CN¥17.27	+0.64%	1,30,26,903

End-of-day quote Shenzhen S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Jilin Aodong Pharmaceutical Group Co., Ltd.

Company calendar

End-of-day quote Shenzhen S.E. 09/11/2026			5-day change	1st Jan Change
17.11 ^CNY	-0.52%		+1.60%	-12.39%

29/10	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
16/10	Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Interim Profit Distribution Plan for 2026 to Be Implemented (A Shares), payable on October 23, 2026	CI

Market Cap	2.01TCr 300.51Cr 268.23Cr 246.82Cr 224.01Cr 424.54Cr 28TCr 435.07Cr 2.95TCr 1.18TCr 15TCr 1.13TCr 1.1TCr 47TCr	P/E 2024	13.1x	P/E 2025	9.57x
Enterprise Value	1.93TCr 289.66Cr 258.55Cr 237.91Cr 215.93Cr 409.21Cr 27TCr 419.37Cr 2.85TCr 1.13TCr 15TCr 1.09TCr 1.06TCr 46TCr	EV / Sales 2024	7.76x	EV / Sales 2025	9.49x
Free-Float	66.63%	Yield 2024	2.9%	Yield 2025	2.56%

29/10	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
16/10	Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Interim Profit Distribution Plan for 2026 to Be Implemented (A Shares), payable on October 23, 2026	CI
01/09	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for the First Half of 2026	CI
29/08	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09/06	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
21/05	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT
13/05	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2025, Payable on 08 July 2026	CI
29/04	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
20/04	Jilin Aodong Pharmaceutical's Attributable Profit Jumps 54% in 2025	MT
18/04	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
13/02	Aodong Pharmaceutical's Subsidiary Gets Nod to Market 10 Traditional Chinese Medicines	MT
27/01	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Jiangsu Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership) and Other shareholders.	CI
30/25/30	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI

1 day	-0.52%
1 week	+1.60%
Current month	+1.60%
1 month	-0.87%
3 months	-5.63%
6 months	-8.94%
Current year	-12.39%

Jilin Aodong Pharmaceutical Group Co., Ltd. Share Price

Stocks

000623

CNE000000719

Pharmaceuticals

Valuation: Jilin Aodong Pharmaceutical Group Co., Ltd.

Chart: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest news: Jilin Aodong Pharmaceutical Group Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	16.95	17.47
1 month	16.36	17.61
Current year	16.36	20.93
1 year	16.36	21.59
3 years	12.49	22.08
5 years	12.49	22.08
10 years	12.49	29.43

Manager	Title	Age	Since
Shu Qin Guo CEO	Chief Executive Officer	63	17/07/2017
Kai Yang DFI	Director of Finance/CFO	49	01/05/2004
Shu Yuan Zhang DFI	Director of Finance/CFO	54	18/06/2007

Director	Title	Age	Since
Shu Qin Guo BRD	Director/Board Member	63	01/02/2000
Shu Yuan Zhang BRD	Director/Board Member	54	17/07/2020
Xiu Lin Li CHM	Chairman	74	18/05/2005

Date	Insider	Type	Main position	Quantity	% Market Cap.
25/11/25	An Ning Li	Buy		100	0.0000%
29/07/24	Xiu Lin Li	Buy	Chairman	3,50,000	0.0302%
29/07/24	Shu Qin Guo	Buy	Chief Executive Officer	3,20,000	0.0276%

	2024	2025
Net sales	261.06Cr 39Cr 35Cr 32Cr 29Cr 55Cr 3.67TCr 57Cr 384.26Cr 153.16Cr 1.96TCr 146.79Cr 143.65Cr 6.18TCr	233.52Cr 35Cr 31Cr 29Cr 26Cr 49Cr 3.28TCr 51Cr 343.73Cr 137Cr 1.76TCr 131.31Cr 128.5Cr 5.53TCr
Net income	155.14Cr 23Cr 21Cr 19Cr 17Cr 33Cr 2.18TCr 34Cr 228.36Cr 91Cr 1.17TCr 87Cr 85Cr 3.67TCr	239.52Cr 36Cr 32Cr 29Cr 27Cr 51Cr 3.36TCr 52Cr 352.56Cr 140.52Cr 1.8TCr 134.68Cr 131.8Cr 5.67TCr
Net Debt	-39Cr -5.78Cr -5.16Cr -4.75Cr -4.31Cr -8.17Cr -541.97Cr -8.37Cr -57Cr -23Cr -290.15Cr -22Cr -21Cr -913.86Cr	-72Cr -11Cr -9.68Cr -8.91Cr -8.09Cr -15Cr -1.02TCr -16Cr -106.57Cr -42Cr -544.28Cr -41Cr -40Cr -1.71TCr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JILIN AODONG PHARMACEUTICAL GROUP CO., LTD.	-0.52%	+1.60%	-19.14%	+5.10%	301.95Cr
ELI LILLY AND COMPANY	+4.28%	+0.07%	+46.07%	+138.78%	1,20600Cr
JOHNSON & JOHNSON	+2.13%	+4.27%	+49.73%	+91.36%	66TCr
ABBVIE INC.	+0.68%	+1.54%	+34.10%	+112.47%	51TCr
ROCHE HOLDING AG	+2.77%	-0.57%	+49.44%	+68.42%	38TCr
MERCK & CO., INC.	+1.38%	+0.27%	+71.48%	+45.30%	36TCr
NOVARTIS AG	+0.29%	-0.24%	+30.84%	+57.23%	31TCr
ASTRAZENECA PLC	+0.98%	+0.76%	+9.04%	+38.31%	29TCr
AMGEN INC.	+1.04%	-0.05%	+43.74%	+76.18%	25TCr
GILEAD SCIENCES, INC.	+1.46%	-0.59%	+43.31%	+125.82%	21TCr
Average	+1.14%	-1.48%	+35.86%	+75.90%	41.83TCr
Weighted average by Cap.	+1.69%	-1.96%	+43.69%	+96.14%